BMS-813160
- Generic Name
- BMS-813160
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H40N8O2
- CAS Number
- 1286279-29-5
- Unique Ingredient Identifier
- 83U7957287
- Background
BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).
- Associated Conditions
- -
- Associated Therapies
- -
Non-small Cell Lung Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence
The non-small cell lung cancer market is driven by increasing NSCLC cases, uptake of immune checkpoint inhibitors, emerging premium therapies, and awareness of mutations. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size from 2019 to 2032 in 7MM. Key companies and therapies include EMD Serono, Merck, AstraZeneca, Bristol-Myers Squibb, and therapies like M1774, C-TIL051, and Osimertinib. FDA approvals for Opdivo and Tagrisso in 2024 highlight advancements in treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath